Ex-cop charged in Floyd's death faces tax evasion counts

Beijing, Mar 25: Around 5,000 people have signed up for the phase I clinical trial of recombinant novel coronavirus vaccine in Chinese city Wuhan where the virus first emerged late last year.

The recruitment for participants ended this week with nearly 5,000 volunteers signing up for the trial, state-run Beijing News reported on Wednesday.

A single-centre, open and dose-escalation phase I clinical trial for recombinant novel coronavirus vaccine (adenoviral vector) will be tested in healthy adults aged between 18 and 60 years, according to the ChiCTR (China Clinical Trial Register).

The trial, led by experts from the Academy of Military Medical Sciences, gained its approval on March 16 and the research is expected to last half a year.

Requiring at least 108 participants, the trial will be conducted in Wuhan, capital of Hubei province, the region worst-affected by the virus in the country, state-run China Daily reported.

Participants will experience 14-day quarantine restrictions after being vaccinated and their health condition will be recorded every day.

Chinese scientists are hastening the development of COVID-19 vaccines through five approaches --- inactivated vaccines, genetic engineering subunit vaccines, adenovirus vector vaccines, nucleic acid vaccines and vaccines using attenuated influenza virus as vectors.

So far, most teams are expected to complete preclinical research in April and some are moving forward faster, Wang Junzhi, an academician with the Chinese Academy of Engineering said.

Wang noted that research and development of COVID-19 vaccines in China is not slower than foreign counterparts and has been carried out in a scientific, standardised and orderly way.

China has stepped up the process to finalise vaccines to counter COVID-19 after Kaiser Permanente research facility in Seattle and Washington stole the march and began human trials.

China lifted tough restrictions on the Hubei province on Wednesday after a months-long lockdown as the country reported no new domestic cases.

But there were another 47 imported infections from overseas, the National Health Commission said. In total, 474 imported infections have been diagnosed in China -- mostly Chinese nationals returning home.

Beijing, May 24: The Chinese virology institute in the city where COVID-19 first emerged has three live strains of bat coronavirus on-site, but none match the new contagion wreaking chaos across the world, its director has said.

Scientists think COVID-19 -- which first emerged in Wuhan and has killed some 340,000 people worldwide -- originated in bats and could have been transmitted to people via another mammal.

But the director of the Wuhan Institute of Virology told state broadcaster CGTN that claims made by US President Donald Trump and others that the virus could have leaked from the facility were "pure fabrication".

"Now we have three strains of live viruses... But their highest similarity to SARS-CoV-2 only reaches 79.8 percent," she said, referring to the coronavirus strain that causes COVID-19.

US demands immediate start to WHO review

The United States called on the World Health Organisation on Friday to begin working immediately on investigating the source of the novel coronavirus, as well as its handling of the response to the pandemic.

One of their research teams, led by Professor Shi Zhengli, has been researching bat coronaviruses since 2004 and focused on the "source tracing of SARS", the strain behind another virus outbreak nearly two decades ago.

"We know that the whole genome of SARS-CoV-2 is only 80 percent similar to that of SARS. It's an obvious difference," she said.

"So, in Professor Shi's past research, they didn't pay attention to such viruses which are less similar to the SARS virus."

Conspiracy rumours that the biosafety lab was involved in the outbreak swirled online for months before Trump and US Secretary of State Mike Pompeo brought the theory into the mainstream by claiming that there is evidence the pathogen came from the institute.

The lab has said it received samples of the then-unknown virus on December 30, determined the viral genome sequence on January 2 and submitted information on the pathogen to the WHO on January 11.

Wang said in the interview that before it received samples in December, their team had never "encountered, researched or kept the virus."

"In fact, like everyone else, we didn't even know the virus existed," she said. "How could it have leaked from our lab when we never had it?"

The World Health Organization said Washington had offered no evidence to support the "speculative" claims.

In an interview with Scientific American, Shi said the SARS-CoV-2 genome sequence did not match any of the bat coronaviruses her laboratory had previously collected and studied.

Feb 13: Two Indian crew on board a cruise ship off the Japanese coast have tested positive for the novel coronavirus, the Indian Embassy in Japan said on Wednesday as authorities confirmed that 174 people have been infected with the deadly disease.

The cruise ship Diamond Princess with 3,711 people on board arrived at the Japanese coast early last week and was quarantined after a passenger who de-boarded last month in Hong Kong was found to be the carrier of the novel virus on the ship.

A total of 138 Indians, including passengers and crew, were on board the ship.

“Due to the suspicion of novel coronavirus (nCoV) infection, the ship has been quarantined by the Japanese authorities till February 19, 2020,” the embassy said in a statement.

“Altogether 174 people have been tested positive for nCoV, including two Indian crew members,” it said.

All the infected people have been taken to hospitals for adequate treatment, including further quarantine, in accordance with the Japanese health protocol, it said.